New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
08:36 EDTMRK, BIIB, SSNLFMerck, Samsung Bioepis enter collaboration agreement
Merck (MRK) and Samsung Bioepis, a joint venture between Samsung (SSNLF) Biologics and Biogen (BIIB), announced that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. Under the terms of the agreement, the companies will collaborate on clinical development, regulatory filings and manufacturing. If approved, Merck will commercialize this candidate. This collaboration builds on the agreement made by the two companies in February 2013 to develop and commercialize multiple biosimilar candidates.
News For MRK;SSNLF;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 29, 2015
06:05 EDTSSNLFNotebook demand expected to be weaker than expected in 2H15, DigiTimes reports
Subscribe for More Information
June 26, 2015
06:24 EDTSSNLFElliott lobbies Korean shareholders to block Samsung C&T, Cheil deal, WSJ says
A team from U.S. hedge fund Elliott told Samsung unit Samsung C&T’s CFO at an April 9 meeting that a merger with Cheil Industries would not be in the best interests of shareholders, including Elliott, the Wall Street Journal reports, citing a person familiar with the matter. Elliott is trying to block the deal, seeking a court injunction and telling investors to block the deal at a shareholder vote next month, the report says. South Korean shareholders in Samsung C&T have begun to voice their concerns over the deal, with “dozens” of them filing court petitions arguing the deal unfairly undervalues Samsung C&T, the report says. Reference Link
05:21 EDTBIIBBiogen, Sobi announce EMA validates MAA for Alprolix
Biogen and Swedish Orphan Biovitrum AB, or Sobi, announced that the European Medicines Agency, or EMA, has accepted the Marketing Authorization Application, or MAA, of Alprolix, a recombinant factor IX Fc fusion protein product candidate for the treatment of hemophilia B. This validation signifies the initiation of the EMA’s review process. The MAA includes results from two global, Phase 3 clinical trials examining the efficacy, safety and pharmacokinetics of ALPROLIX for hemophilia B: the pivotal B-LONG study for previously treated adults and adolescents, and Kids B-LONG study for previously treated children under age 12.
June 25, 2015
12:59 EDTBIIBOptions with increasing implied volatility
Subscribe for More Information
10:29 EDTSSNLFBarnes & Noble says relationship with Samsung 'excellent'
Subscribe for More Information
07:29 EDTSSNLFCheil, Samsung C&T deal could increase shareholder returns, Reuters reports
Subscribe for More Information
05:53 EDTSSNLFSamsung expects SUHD TV sales to reach 15K in 1H15, DigiTimes reports
Subscribe for More Information
June 24, 2015
11:16 EDTBIIBOptions with increasing implied volatility
Options with increasing implied volatility: WMB AMZN CMG BIIB VMW QLIK ISRG FB UA FFIV
09:07 EDTMRKCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
June 23, 2015
16:02 EDTSSNLFRed Hat, Samsung form strategic alliance
Subscribe for More Information
11:00 EDTBIIBOptions with increasing implied volatility
Options with increasing implied volatility:TRIP WPZ CMG BIIB WMB AMZN ISRG VMW
07:55 EDTBIIBBiogen's Tysabri in SPMS a $1B-$2B opportunity, says Morgan Stanley
Subscribe for More Information
06:05 EDTSSNLFIntel pushing into SSD market and hope to surpass Samsung in 2016, DigiTimes says
Intel (INTC) is looking to push into the SSD market with its newest 750 series SSDs with technology able to enhance the transmission speed, reports DigiTimes. According to sources from the upstream supply chain, the company is also offering price cuts on its existing products in order to narrow its gap with the largest vendor Samsung (SSNLF). Sources also expect Intel to draw near to Samsung in 2H15 and may even have a chance to surpass Samsung in 2016. Reference Link
06:05 EDTSSNLFSamsung pushing to release Galaxy S7 in 2H15, DigiTimes reports
Subscribe for More Information
06:05 EDTSSNLFNo clear prospects for PC component suppliers until July, DigiTimes reports
There are no clear business prospects for PC component suppliers until July, reports DigiTimes. According to sources in the supply chain, Intel's decision to delay the launch of its Skylake platform has weakened market demand for notebooks and other PC systems. The planned release of Microsoft (MSFT) Windows 10 may also affect the production of PC makers. Reference Link
June 22, 2015
17:55 EDTSSNLFITC staff supports clearing Samsung, Qualcomm, in NVIDIA case, Bloomberg says
The U.S. International Trade Commission staff recommends that Samsung Electronics (SSNLF) and Qualcomm (QCOM) be absolved of patent-infringement accusations brought by Nvidia (NVDA), Bloomberg reports. Reference Link
14:42 EDTSSNLFOculus potential not reflected in Facebook's stock price, Piper Jaffray says
Subscribe for More Information
June 21, 2015
14:44 EDTSSNLFFitbit shares likely to see 'typical IPO' subpair gains, Barron's says
Subscribe for More Information
13:14 EDTMRKMerck shares could return 25%, Barron's says
Subscribe for More Information
June 19, 2015
07:15 EDTSSNLFCourt to rule July 1 on Elliott’s bid to block Samsung deal, Reuters reports
A South Korean court said it will rule by July 1 on U.S. hedge fund Elliott’s request to block a Samsung C&T Corp, a unit of Samsung, shareholder vote on an $8B buyout offer from Cheil Industries, Reuters reports. Elliott told the court that Cheil’s offer was built to pave the way for a leadership succession in the Samsung conglomerate and did not serve the best interests of their shareholders, the report says. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use